Alpha‐synuclein co‐pathology in a real‐world early Alzheimer's disease cohort
Alzheimer's & Dementia · 2026-03 · 22 (3)
DOI: 10.1002/alz.71240 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 24.03.2026. Verfasst von Tamara Shiner und 15 weiteren Autor:innen. Beteiligte Einrichtung: Cognitive Neurology Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel. Hauptthemen laut MEDLINE: alpha-Synuclein, Alzheimer Disease. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
BACKGROUND Most Alzheimer's disease (AD) cases show mixed pathology, with α‐synuclein (αSyn) aggregates present in a substantial proportion. The cerebrospinal fluid (CSF) α‐synuclein seed amplification assay (αS‐SAA) enables in vivo detection of pathogenic αSyn aggregates, but its clinical significance remains unclear. METHODS We prospectively evaluated 108 individuals with mild cognitive impairment or mild dementia due to suspected AD undergoing lumbar puncture for anti‐amyloid therapy (ATT) eligibility. CSF AD biomarkers and αS‐SAA were analyzed alongside cognitive, olfactory, and rapid eye movement sleep behavior disorder (RBD) assessments. RESULTS Of 65 participants with biomarker‐confirmed AD, 21 (32.3%) were αS‐SAA positive. Positivity was linked to older age at testing and self‐reported olfactory impairment ( P = 0.004), but not other demographic or cognitive features. Within the αS‐SAA–positive group, RBD presence correlated with faster seeding kinetics. CONCLUSIONS αS‐SAA positivity is common in early AD and associated with olfactory dysfunction. Longitudinal follow‐up is required to test if assay status predicts response to ATTs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cognitive Neurology Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel.
- Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
- Movement Disorders Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel.
- Laboratory of Biomarkers and Genomics of Neurodegeneration, Tel Aviv, Israel.
- Division of Clinical Laboratories, Tel Aviv Medical Center, Tel Aviv, Israel.
Zitieren
APA
Shiner, T., Nathan, T., Levy, M. H., David, A. B., Omer, N., Awad, A. A., Ash, E., Weisz, M. G., Goldstein, O., Alcalay, Y., Regev, K., Lamoureux, J., Van Keuren-Jensen, K., Blauwendraat, C., Alcalay, R. N., & Bregman, N. (2026). Alpha‐synuclein co‐pathology in a real‐world early Alzheimer's disease cohort. Alzheimer's & Dementia, 22(3). https://doi.org/10.1002/alz.71240
Vancouver
Shiner T, Nathan T, Levy MH, David AB, Omer N, Awad AA, et al. Alpha‐synuclein co‐pathology in a real‐world early Alzheimer's disease cohort. Alzheimer's & Dementia. 2026;22(3). doi:10.1002/alz.71240
BibTeX
@article{Shiner2026,
author = {Shiner, Tamara and Nathan, Talya and Levy, Mori Hai and David, Aya Bar and Omer, Nurit and Awad, Anan Abu and Ash, Elissa and Weisz, Mali Gana and Goldstein, Orly and Alcalay, Yifat and Regev, Keren and Lamoureux, Jennifer and Van Keuren-Jensen, Kendall and Blauwendraat, Cornelis and Alcalay, Roy N and Bregman, Noa},
title = {Alpha‐synuclein co‐pathology in a real‐world early Alzheimer's disease cohort},
journal = {Alzheimer's & Dementia},
year = {2026},
volume = {22},
number = {3},
doi = {10.1002/alz.71240}
}
EUVIMED